Share this article
Share this article
EMERYVILLE, Calif., April 13, 2021 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced the appointment of James Chung, M.D., Ph.D., as the Company's first Chief Medical Officer. Dr. Chung brings extensive biopharmaceutical industry experience working across the entire drug development process focused on autoimmune diseases and has dedicated a significant part of his career working in translational medicine and early clinical development. By leading the Company's Clinical Development organization, he will contribute to Kyverna's transition to a clinical-stage company.
James Chung, M.D., Ph.D., Chief Medical Officer, Kyverna Therapeutics